A Functional Screening Identifies a New Organic Selenium Compound Targeting Cancer Stem Cells: Role of c‐Myc Transcription Activity Inhibition in Liver Cancer
Authors:
Open Access
- 2 June 2022
- journal article
- research article
- Published by Wiley in Advanced Science
- Vol. 9 (22) , e2201166
Abstract
Cancer stem cells (CSCs) are reported to play essential roles in chemoresistance and metastasis. Pathways regulating CSC self‐renewal and proliferation, such as Hedgehog, Notch, Wnt/β‐catenin, TGF‐β, and Myc, may be potential therapeutic targets. Here, a functional screening from the focused library with 365 compounds is performed by a step‐by‐step strategy. Among these candidate molecules, phenyl‐2‐pyrimidinyl ketone 4‐allyl‐3‐amino selenourea (CU27) is chosen for further identification because it proves to be the most effective compound over others on CSC inhibition. Through ingenuity pathway analysis, it is shown CU27 may inhibit CSC through a well‐known stemness‐related transcription factor c‐Myc. Gene set enrichment analysis, dual‐luciferase reporter assays, expression levels of typical c‐Myc targets, molecular docking, surface plasmon resonance, immunoprecipitation, and chromatin immunoprecipitation are conducted. These results together suggest CU27 binds c‐Myc bHLH/LZ domains, inhibits c‐Myc‐Max complex formation, and prevents its occupancy on target gene promoters. In mouse models, CU27 significantly sensitizes sorafenib‐resistant tumor to sorafenib, reduces the primary tumor size, and inhibits CSC generation, showing a dramatic anti‐metastasis potential. Taken together, CU27 exerts inhibitory effects on CSC and CSC‐associated traits in hepatocellular carcinoma (HCC) via c‐Myc transcription activity inhibition. CU27 may be a promising therapeutic to treat sorafenib‐resistant HCC.Keywords
Funding Information
- National Key Research and Development Program of China (2017YFA0103100, 2017YFA0103103, 2017YFA0103104)
- National Natural Science Foundation of China (81773137)
This publication has 56 references indexed in Scilit:
- The evolving concept of cancer and metastasis stem cellsJournal of Cell Biology, 2012
- MYC on the Path to CancerCell, 2012
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- Sonic Hedgehog Pathway Is Essential for Maintenance of Cancer Stem-Like Cells in Human Gastric CancerPLOS ONE, 2011
- In Vitro Cytotoxicity and In Vivo Efficacy, Pharmacokinetics, and Metabolism of 10074-G5, a Novel Small-Molecule Inhibitor of c-Myc/Max DimerizationThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Pro-proliferative FoxM1 is a target of p53-mediated repressionOncogene, 2009
- Extracellular thiol-assisted selenium uptake dependent on the x c − cystine transporter explains the cancer-specific cytotoxicity of seleniteProceedings of the National Academy of Sciences, 2009
- Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc–Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in miceCancer Chemotherapy and Pharmacology, 2008
- The great MYC escape in tumorigenesisCancer Cell, 2005
- MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancerNature, 2004